|
Pharmos Corporation is a bio-pharmaceutical company focused on the discovery, development and commercialization of therapeutics for the central nervous system (CNS), peripheral nervous system, ophthalmologic, oncologic and other key healthcare markets.
Pharmos uses state-of-the-art drug design, synthesis, screening, and delivery methodologies to improve targeted molecules and enhance their therapeutic benefits. Pharmos is committed to developing drugs with superior safety and efficacy. Driven by its mission to develop drugs with superior safety and efficacy, Pharmos uses advanced methods of drug design, combinatorial chemistry and screening tools to invent new and to improve existing therapeutic compounds.
Pharmos' proprietary technologies have resulted in products that have increased efficacy and/or reduced side effects relative to their precursors and to competing products. Pharmos has successfully developed and commercialized two proprietary ophthalmic products, Lotemax® and Alrex®. A third ophthalmic product, Loteprednol Etabonate-Tobramycin (LE-T), is completing advanced clinical development. Pharmos is developing dexanabinol (HU-211) for traumatic brain injury (TBI) and stoke. In Phase II clinical trials with severe TBI patients, dexanabinol has demonstrated excellent results.... Pharmos has developed proprietary and novel lipid-based Drug Delivery Systems (DDS), the Emulsome and the SME, with a wide range of therapeutic applications for a variety of drugs that are delivered by parenteral, dermal or oral routes of administration. Also Pharmos Ltd. Israel
Activity:
- Manufacturing
- Research & Development
Product / Technology type(s) covered:
- Bio
- NCE (new chemical entities)
- Pharmaceuticals / Therapeutics
- Technology
Therapeutic targets:
- Central nervous system
- Neurology
- Oncology
- Ophthalmology
|
|
Company Contact
|
Pharmos Corp.
United States of America
Phone:
FAX:
Website: www.pharmoscorp.com
|
|
Add
Company
Subscribe
Search
Contact
